People in the study will have either closed wounds, such as stitched cuts, or open wounds, such as small biopsy wounds made during the study. After treatment, the wounds will be followed over time while they heal, and the scars will be checked later. The study will also look at how safe the treatment is and whether any side effects occur, such as skin reactions or other body reactions. Some scars will also be looked at with medical pictures and ultrasound, which is a test that uses sound waves to create images inside the body.

Scar prevention is the main focus of this trial, and the study is designed to compare three verteporfin doses with saline in both open and closed wound types. The study will continue until the healing and scar checks are completed after treatment.

The study is for people whose cancer has gotten worse after treatment with platinum-based chemotherapy and anti-PD-L1 or anti-PD-1 therapy, which are treatments that help the immune system fight cancer. Treatment of physician’s choice may include topotecan, tisotumab vedotin, irinotecan, pemetrexed, gemcitabine, or vinorelbine, and some medicines may be given with supportive care such as paracetamol, H2-receptor antagonists, and glucocorticoids to help reduce side effects. The study is randomized, which means treatment is assigned by chance, and it is open-label, which means both the study team and the participant know which treatment is being given.

The study has an initial part and then a larger comparison part. In the first part, MK-2870 is given to gather early information about how it acts in the body and how well it is tolerated. In the main part, MK-2870 is compared with other available cancer treatments. Treatment is given over time, with regular study visits and checks for side effects and general health while the cancer is being followed.

The purpose of the study is to determine if niraparib can help patients live longer without the disease getting worse, compared to temozolomide. Participants in the study will be randomly assigned to receive either niraparib or temozolomide. The study will monitor the participants over time to see how the treatments affect their health and the progression of their glioblastoma.

Throughout the study, researchers will also look at how the treatments impact overall survival, which means the length of time patients live after starting the treatment. Additionally, the study will assess the participants’ symptoms, quality of life, and any side effects they may experience. This information will help determine the safety and effectiveness of niraparib compared to temozolomide for treating this specific type of glioblastoma.

Each person will take the assigned tablet twice daily for about four months. During this time, they will complete a simple questionnaire called the Comprehensive Pain Assessment Tool Short Form (COMPAT‑SF) to record how much pain they feel, and another survey called the Short Form 36 (SF‑36) to evaluate overall well‑being. Blood samples will be taken to measure a protein linked to inflammation, known as high‑sensitivity C‑reactive protein (hs‑CRP), and the amount of opioid medication used will be expressed as oral morphine equivalents (OME). These checks are done at regular clinic visits, but no detailed technical procedures are required from the participants.

Safety is closely watched throughout the trial; doctors will look for any stomach irritation, bleeding, kidney changes, heart problems, or liver issues that might arise. Any unwanted effects are recorded and evaluated to ensure the treatment is well tolerated. The information gathered will help determine if the medication offers a meaningful benefit for people living with this condition.

The standard treatment in this study includes bevacizumab, oxaliplatin, fluorouracil, and calcium folinate. INCA33890 is given by vein, and the other medicines are also given as injections or infusions into a vein. People in the study are assigned by chance to one of two groups: one group receives INCA33890 with the standard treatment, and the other group receives placebo with the standard treatment. The study is blinded, which means the treatment group is not known to the people taking part or to the study team during the study.

After treatment starts, the study team follows how the cancer responds and how long the treatment helps keep the disease under control. The study also looks at how long people live and at side effects, which are unwanted health problems caused by a treatment.

People in the study are placed into one of the treatment groups by chance. Treatment is given as intravenous infusion, which means medicine is delivered slowly through a vein. The study is planned to follow people over time while they receive treatment and after treatment ends to see how they do. The trial also watches for side effects, including cytokine release syndrome, a strong immune reaction, and ICANS, which is a group of brain and nerve symptoms that can happen with some immune treatments.

Obrixtamig is also known by the code name BI 764532. It is a type of treatment called a T cell engager, which is designed to help the immune system find and attack cancer cells that have DLL3 on their surface. The study is for previously untreated cancer that is DLL3-positive, meaning the cancer cells have this marker.

The purpose of the study is to see which medication provides better control of the disease after one year. Participants will receive their assigned medication regularly for up to 52 weeks, with scheduled doctor visits to check how they feel and to perform simple tests that look for signs of healing. The main goal is to determine whether patients achieve “deep remission,” meaning they have no symptoms and their intestinal lining looks normal.

The purpose of the study is to assess how safe the investigational drug is and to determine the appropriate dose when used alone or in combination with the hormone therapies.

Participants will first undergo screening tests, then begin taking the study medication in a series of visits. Depending on the study arm, they may receive an injection of the hormone blocker, a daily pill, or both, alongside the oral investigational drug. Throughout the study they will have regular check‑ups that include blood work, vital‑sign measurements, and heart rhythm checks to monitor safety. Treatment continues until the cancer shows growth, side effects become unacceptable, or the study ends.

The purpose of the study is to test whether BMS-986504 combined with nab-paclitaxel and gemcitabine can help people live longer and delay the time until the cancer gets worse compared to placebo combined with nab-paclitaxel and gemcitabine. The study will also look at whether the combination treatment can shrink tumors and control tumor growth. People joining the study must have their cancer confirmed through tissue samples and must have evidence of the MTAP deletion in their tumor. The cancer must have spread to other parts of the body with at least one area that can be measured on scans.

During the study, people will be randomly assigned to receive either BMS-986504 or placebo, both given together with nab-paclitaxel and gemcitabine. The study will track how long it takes for the cancer to worsen on scans and how long people survive. Researchers will also measure how much tumors shrink, how long any shrinkage lasts, and how many people experience tumor control or shrinkage. People in the study must not have received any cancer treatment for their spread disease before joining, although they may have received up to one cycle of nab-paclitaxel and gemcitabine before being assigned to a treatment group.

The purpose of the study is to find out what doses of BMS-986517 are safe and how much people can tolerate in order to choose the best dose for future use, and to check if giving BMS-986517 at the chosen dose continues to be safe for people with specific cancers. The study will also monitor how often side effects occur, including serious side effects and those that might require stopping treatment. Additionally, the study will track whether tumors shrink and how long any responses last, as well as how the medication moves through and is processed by the body.

The study is divided into two parts. The first part focuses on testing different doses to determine which are safe and well tolerated. The second part uses the doses chosen from the first part to further evaluate safety in people with specific types of cancer. Participants will receive the medication through infusion and will be monitored for side effects during the first 21 days and throughout the treatment period, which can last up to 3 years from the first treatment, with additional monitoring for 30 days after the last treatment.

The purpose of this research is to test whether immunotherapy treatment, which usually works only for a small number of colorectal cancer patients, could be made effective for more patients when combined with other medications. The study will also look for biological markers that might help predict which patients will respond best to this treatment.

During the study, which may last up to 24 months, participants will receive a combination of these medications. The treatment involves taking temozolomide and capecitabine tablets daily, while ipilimumab and nivolumab are given through an intravenous infusion at scheduled times. Throughout the treatment, doctors will monitor how the cancer responds to these medications through regular medical check-ups and imaging tests.

The purpose of this research is to determine which medication provides better and safer conditions for placing the breathing tube in adult patients who need tracheal intubation during surgery. The study will look at how well each medication works and any possible side effects that may occur during or after the procedure.

During the study, patients will receive either remifentanil or rocuronium before the breathing tube is inserted. Doctors will monitor patients for any complications that might occur within 24 hours after the procedure, including effects on breathing, heart function, or discomfort in the throat. The medication doses are carefully calculated based on each patient’s weight, with remifentanil given at up to 4 micrograms per kilogram and rocuronium at up to 0.6 milligrams per kilogram.

At the start, pembrolizumab is given over a period of time, with regular medical checks during treatment. After treatment, the cancer is checked again with tests such as a CT scan, which is a special X-ray picture of the body, and an endoscopy, which is a thin tube test used to look inside the bowel. Based on these results, some people may go on to surgery, while others may be monitored closely without immediate surgery. The study also follows health over time to learn about possible side effects, recovery, and general well-being.

People in the study are assigned by chance to one of the two treatment groups, and neither the study team nor the participants know which treatment is being given. The treatment is taken as tablets over time, with regular study visits during the trial. During these visits, the study team checks for side effects and overall health, and asks about symptoms and daily well-being.

The trial is looking at adults with advanced kidney cancer who have already received treatment with PD-1/L1 and VEGF-TKI medicines, either one after the other or together. PD-1/L1 and VEGF-TKI are types of cancer medicines that act in different ways to slow tumor growth. The study follows participants while they receive treatment and for some time afterward to understand the effects of the medicine combination over time.

The study medication will be given through intramuscular injections, meaning the medicine is injected directly into muscles. Participants will receive either Xeomin or placebo injections over a period of 6 months. The treatment involves multiple injection sessions, with the medication being administered at specific intervals throughout the study period.

During the trial, participants will need to keep track of their headaches and migraine days using a headache diary. The study will monitor how the treatment affects the frequency of migraine days, headache days, and the use of other migraine medications. The researchers will also track any side effects that may occur during the treatment period. The total study duration for each participant will be approximately 36 weeks.

The main purpose of this research is to determine if Xeomin is more effective than placebo in reducing the number of monthly migraine days. The study involves different doses of the medication, with participants receiving either Xeomin or placebo injections. The treatment period lasts for 6 months, during which participants will receive multiple injections.

The medication being tested, Xeomin, is a purified form of botulinum toxin that is free from complexing proteins. The study will monitor how the treatment affects the frequency of migraine days, headache days, and the use of acute migraine medications. Throughout the study, participants will need to keep track of their migraine episodes and any changes in their condition.

The treatment will involve receiving regular injections of the study medications for up to 52 weeks. Mirikizumab is a type of medication called a monoclonal antibody, which works by targeting specific parts of the immune system. Tirzepatide is a medication that can help with weight management. Some participants will receive both active medications, while others will receive Mirikizumab with placebo.

The study will measure how many participants achieve two goals at the same time: improvement in their Ulcerative Colitis symptoms and a significant reduction in their body weight. The medications will be given through injections either under the skin or into a vein, depending on the specific medication being administered.

Participants in the study will be randomly assigned to receive either BHV-7000 or a placebo, which looks like the medication but does not contain the active ingredient. The study will last for about eight weeks, during which participants will take the medication or placebo daily. Researchers will monitor the participants to see if there is a reduction in the number of seizures they experience. The goal is to find out if BHV-7000 can help reduce seizures by at least 50% in those taking the medication compared to those taking the placebo.

Throughout the study, the safety and tolerability of BHV-7000 will be closely observed. This means researchers will keep track of any side effects or adverse reactions participants might experience. The study aims to provide valuable information on whether BHV-7000 can be a beneficial treatment option for people with Refractory Focal Onset Epilepsy, potentially offering a new way to manage this challenging condition.

Participants in the study will receive either Barzolvolimab or a placebo, which is a substance that looks like the medication but does not contain any active ingredients. The study will last for several weeks, during which participants will receive regular doses of the medication or placebo. Throughout the study, participants will be monitored to assess changes in their urticaria symptoms, particularly focusing on the reduction of hives and itching. The main goal is to see if Barzolvolimab can significantly improve the condition compared to the placebo by the end of the study period.

The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are unbiased and reliable. The trial will also involve regular check-ups and assessments to track the progress and any potential side effects. The findings from this study could provide valuable insights into the effectiveness of Barzolvolimab as a treatment option for those suffering from Chronic Spontaneous Urticaria.

The purpose of this study is to determine how safe and tolerable Tolebrutinib is over a long period. Participants will take the medication orally, and the study will last for up to 36 months. During this time, researchers will monitor participants for any adverse events, which are unwanted effects that may occur during the study. The study will also look at how the medication affects the progression of disability in participants with MS and track any changes in the brain using Magnetic Resonance Imaging (MRI), a type of scan that provides detailed images of the brain.

In addition to Tolebrutinib, the study involves other substances like Anhydrous Cholestyramine, which is used to bind certain substances in the intestines, and Magnetic Resonance Imaging Contrast Media, which helps improve the clarity of MRI images. These substances are used to support the study’s objectives and ensure accurate monitoring of the participants’ health. The study aims to provide valuable information on the long-term use of Tolebrutinib in managing Multiple Sclerosis.

Participants in the study will be randomly assigned to receive either hydroxychloroquine sulfate or a placebo, which is a tablet that looks like the medication but does not contain any active ingredients. The study will monitor the participants throughout their pregnancy to observe any effects on pregnancy loss, premature birth, and other related outcomes. The medication will be taken orally in the form of film-coated tablets.

The trial will also assess the safety and tolerability of hydroxychloroquine sulfate for both the mother and the newborn. The study is expected to continue until the end of 2027, with participants being followed closely to gather comprehensive data on the effects of the treatment. The ultimate goal is to determine whether hydroxychloroquine sulfate can be a beneficial treatment option for improving pregnancy outcomes in women with antiphospholipid antibodies.

Participants in the study will receive medications through an intravenous infusion, which is a method of delivering medicine directly into a vein. The study involves comparing different combinations of drugs to see how they affect progression-free survival, a term used to describe the length of time during and after treatment that a person lives with the disease without it getting worse. Other factors being observed include overall survival and the quality of life, which tracks how well a person can perform daily activities and their general well-being during the study.

The purpose of the study is to evaluate how well GSK3862995B works compared with placebo in people with bronchiectasis. The study will look at whether the medication can reduce the number of times patients experience flare-ups of their condition over time. The study will also examine the safety of the medication, how the body’s immune system responds to it, and how the medication moves through and is processed by the body.

During this study, participants will receive repeated doses of either GSK3862995B or placebo over a period of time. The study is designed so that neither the participants nor the doctors will know who is receiving the actual medication and who is receiving the placebo until the study is completed. Throughout the study, doctors will monitor how often participants experience flare-ups of their bronchiectasis, how long it takes before the first flare-up occurs, and how many severe flare-ups happen. The study is expected to continue until late 2027.

The main goal of the study is to see how well CagriSema works at lowering blood sugar levels compared to semaglutide alone, as measured by a blood test called HbA1c that shows average blood sugar over several months. The study will also look at how these medications affect body weight, blood pressure, cholesterol levels, and other health measurements. Researchers want to understand if the combination medication works better than the individual medications at helping people reach target blood sugar levels and lose weight. The study will also measure how much time blood sugar levels stay within a healthy range using a continuous glucose monitor, which is a small device that tracks sugar levels throughout the day.

Participants will receive their assigned treatment for 68 weeks, with the entire study lasting about 75 weeks. During this time, they will have regular visits to check their blood sugar, weight, blood pressure, and overall health. The study will also ask participants questions about their quality of life and satisfaction with their diabetes treatment. Safety will be carefully monitored throughout the study, including checking for side effects and episodes of low blood sugar, which can occur when blood sugar drops too low and may cause symptoms like shakiness or confusion.

The main purpose of this study is to compare how long people live when treated with the investigational medicine compared to docetaxel. The study will look at this in all people whose tumors have PD-L1 levels of at least one percent, and also specifically in those whose tumors have PD-L1 levels of fifty percent or higher. People taking part will be randomly assigned to receive either the investigational medicine or docetaxel. The study will also look at other things like how well the tumors respond to treatment, how long any response lasts, and what side effects occur with each treatment.

During the study, participants will receive their assigned treatment for up to sixty months. Those receiving the investigational medicine will get it at a dose based on their body weight, while those receiving docetaxel will get it at a dose based on their body surface area. The study team will regularly check how the cancer is responding to treatment and monitor for any side effects. Participants will also be asked about their quality of life and any symptoms they are experiencing. Blood samples will be taken from those receiving the investigational medicine to measure drug levels in the body and to check for immune responses to the medicine. Tumor tissue samples will also be collected for testing to help understand how the treatments work.

The purpose of this study is to find out if BAY 3713372 is safe, how it affects the body, what side effects it may cause, and whether it can help treat these types of tumors. The study will also determine the right dose of this medicine to use, both when given alone and when combined with other cancer treatments. Additionally, researchers want to understand how the medicine moves through the body and how it may affect tumor growth.

The study will happen in two main parts. In the first part, called dose escalation, different doses of BAY 3713372 will be tested in small groups of people to find a safe and effective dose. Participants will be closely monitored for any side effects, and blood samples will be taken to measure the levels of the medicine in the body. In the second part, called dose expansion, a larger number of people with specific types of MTAP-deleted tumors will receive the selected dose of BAY 3713372, either alone or combined with other cancer treatments. Throughout the study, participants will have regular check-ups, scans to measure their tumors, and blood tests. The treatment is given in cycles, with each cycle lasting 21 days, and participants may continue treatment as long as it is helping them and not causing unacceptable side effects.

The purpose of this study is to compare how well the combination of belzutifan and zanzalintinib works against cabozantinib in treating advanced kidney cancer. The study will look at how long people live without their cancer getting worse and how long they live overall. The study will also measure how many people respond to treatment, meaning their cancer shrinks or disappears, and how long that response lasts.

During the study, people will be randomly assigned to receive either the combination treatment or cabozantinib alone. The study will track any unwanted effects that occur and whether people need to stop treatment because of these effects. The study will also measure quality of life and how well people are able to carry out daily activities using questionnaires that ask about physical health, ability to perform usual activities, and symptoms related to kidney cancer. The study will continue to follow people over time to gather information about how the treatments affect their cancer and overall health.

The medications being studied include clopidogrel (a blood-thinning medication), acetylsalicylic acid (also known as aspirin), and two types of cholesterol-lowering medications called atorvastatin and rosuvastatin. The purpose is to determine if these treatments, along with managing other health risk factors, can reduce the risk of serious heart and brain problems over a three-year period.

During the study, participants will take their assigned medications daily and undergo various health assessments. These will include MRI scans of the brain to check for changes, tests of memory and thinking abilities, and evaluations of daily functioning and quality of life. The study will track any heart problems, strokes, or bleeding issues that occur during the treatment period.

The purpose of this research is to determine how well zoldonrasib works in treating patients with this specific type of lung cancer. The medication comes in tablet form and is taken by mouth. During the study, patients will receive zoldonrasib daily, with the maximum daily dose being 1200 mg. The treatment period may last up to 9 months.

Throughout the study, doctors will monitor patients’ health and track how their cancer responds to the treatment. They will check the size of tumors and watch for any changes in the patient’s condition. The study will also look at how long the treatment remains effective and track any side effects that may occur. Regular medical examinations and blood tests will be performed to ensure patient safety during the treatment period.

The purpose of this study is to determine if ALXN2420 can help lower levels of a hormone called IGF-1 in people with acromegaly when combined with standard treatments. The study compares ALXN2420 to placebo, with both being given alongside regular acromegaly medications. The treatment period lasts for 15 weeks, during which participants receive either ALXN2420 or placebo through injections under the skin.

Throughout the study, participants continue their regular acromegaly medications, which are given as injections either into the muscle or under the skin once every four weeks. The study monitors how well the combination of treatments works by measuring hormone levels and tracking any changes in symptoms. Participants also complete questionnaires about their quality of life and overall health during the study period.

The study consists of two parts. The first phase aims to find the right dose of the medications and assess their safety. The second phase focuses on determining how well the treatments work in fighting the cancer. The types of cancer being studied include non-small cell lung cancer, biliary tract cancer, pancreatic cancer, gastroesophageal cancer, and glioblastoma (a type of brain tumor), as long as they have the specific MTAP genetic characteristic.

During the study, participants will receive either S095035 alone or in combination with TNG462. The researchers will monitor how the medications affect the tumors and track any side effects that may occur. They will also study how the medications are processed by the body and measure various aspects of the treatment’s effectiveness, such as how long it takes for tumors to respond and how long the response lasts.

The study aims to determine which treatment combination is more effective at preventing the disease from getting worse. Patients will receive either tablets of sonrotoclax or venetoclax to take by mouth, along with infusions of obinutuzumab or rituximab given through a vein. The medications will be given over several months according to a specific schedule.

Throughout the study, doctors will monitor how well the treatments work by performing various tests and examining patients regularly. They will check for the presence of cancer cells in the blood, measure how long patients live without their disease getting worse, and track any side effects that may occur. The study is expected to continue until the end of 2031.

The research will assess whether rocatinlimab can improve the condition of patients’ skin by reducing the severity and affected areas of eczema. The study will measure improvements in skin appearance, reduction in pruritus (itching), decrease in skin pain, and overall quality of life for participants. It will specifically examine whether participants achieve clear or almost clear skin on their face, hands, and other body areas after treatment.

Throughout the 24-week study period, participants will receive either rocatinlimab or placebo and will need to regularly report their symptoms and complete assessments. The research is designed for adults who have had atopic dermatitis for at least 12 months and have not responded adequately to previous treatments for their condition.

Participants may receive different combinations of medications. One group will receive blinatumomab alternating with low-intensity chemotherapy, which is a type of treatment that uses drugs to kill cancer cells. The other group will receive the standard of care, which includes medications such as rituximab, cytarabine, dexamethasone, vincristine sulfate, cyclophosphamide, methotrexate sodium, mercaptopurine, prednisone, idarubicin, asparaginase, and doxorubicin. Other substances mentioned in the study include pegaspargase, crisantaspase, and prednisolone.

The study will monitor how long patients live and how long they stay without the cancer returning. Researchers will also look at the minimal residual disease, which refers to the small number of cancer cells that remain in the body after treatment. Additionally, the study will track how the treatments affect the patients’ quality of life, including levels of pain, tiredness, and physical function.